



Docket No.: 066821-0281

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Reed, John C.
Appl. No. : 10/828,920
Filed : April 20, 2004
Title : NOVEL CARD PROTEINS
INVOLVED IN CELL DEATH
REGULATION

Customer No.: 41552
Confirmation No.: 6166
CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Jun 22, 2006.

L.Ford

Grp./A.U. : 1633
Examiner: : Wehbe, Anne Marie Sabrina

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

Also attached: 1 Information Disclosure Statement
1 PTO Form 1449 (4 pages)
No References attached pursuant to 37 CFR 1.98(d)


The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP

Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:llf
Facsimile: 858.597.1585
Date: June 22, 2006



Docket No.: 066821-0281

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Reed, John C.
Appl. No. : 10/828,920
Filed : April 20, 2004
Title : NOVEL CARD PROTEINS
INVOLVED IN CELL DEATH
REGULATION

Customer No.: 41552
Confirmation No.: 6166
CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Jun 22, 2006

LFord

Grp./A.U. : 1633
Examiner: : Wehbe, Anne Marie Sabrina

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

The references were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 09/388,221, filed September 1, 1999, which is relied upon for an earlier filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR

10/828,920

1.98(d). Applicants will be pleased to provide copies of the references if requested by the Examiner.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP




Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
Phone: 858.535.9001 DLC:llf
Facsimile: 858.597.1585
Date: June 22, 2006

**Please recognize our Customer No. 41552
as our correspondence address.**



INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 066821-0281	SERIAL NO. 10/828,920
	APPLICANT Reed, John C.	
	FILING DATE April 20, 2004	GROUP 1633

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 5,632,994	05-27-1997	REED and SATO	
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	2	WO 96/12016	04-25-1996			Yes	No
	3	WO 99/40102	08-12-1999				
	4	WO 01/00826	01-04-2001				
	5	WO 01/18042	03-15-2001				
	6	WO 01/30971	05-03-2001				
	7	WO 01/66690	09-13-2001				
	8	WO 01/72822	10-04-2001				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	9	AHMAD et al., "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP," <u>Cancer Res.</u> 57(4):615-619 (1997)
	10	BERTIN et al., "Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-κB," <u>J. Biol. Chem.</u> 274(19):12955-12958 (1999)
	11	CARDONE et al., "Regulation of cell death protease caspase-9 by phosphorylation," <u>Science</u> 282(5392):1318-1321 (1998).
	12	CHINNAIYAN et al., "Role of CED-4 in the activation of CED-3," <u>Nature</u> 388(6644):728-759 (1997)
	13	CHINNAIYAN et al., "Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death," <u>Science</u> 275(5303):1122-1126 (1997)
	14	DAMIANO et al., "CLAN, a novel human CED-4-like gene," <u>Genomics</u> . 75(1-3):77-83 (2001)
	15	DIDONATO et al., "A cytokine-responsive IκB kinase that activates the transcription factor NF-κB," <u>Nature</u> 388(6642):548-554 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTY. DOCKET NO. 066821-0281	SERIAL NO. 10/828,920
		APPLICANT Reed, John C.	
		FILING DATE April 20, 2004	GROUP 1633
	16	DING et al., "A single amino acid determines the immunostimulatory activity of interleukin 10," <u>J. Exp. Med.</u> 191(2):213-223 (2000)	
	17	DURFEE et al., "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit," <u>Genes Dev.</u> 7(4):555-569 (1993)	
	18	ECK and WILSON, "Gene based therapy," <u>Goodman & Gilman's the Pharmacological Basis of Therapeutics</u> , ninth edition, Chapter 5, McGraw-Hill, New York, pages 77-101 (1996)	
	19	GEDDES et al., "Human CARD12 is a novel CED4/Apaf-1 family member that induces apoptosis," <u>Biochem. Biophys Res Commun.</u> 284(1):77-82 (2001)	
	20	GERHOLD and CASKEY, "It's the genes! EST access to human genome content," <u>BioEssays</u> 18(12):973-981 (1996)	
	21	GYURIS et al., "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2," <u>Cell</u> 75(4):791-803 (1993)	
	22	HOFMANN and BUCHER, "The CARD domain: a new apoptotic signalling motif," <u>TIBS</u> 22(5):155-156 (1997)	
	23	INOHARA et al., "Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB," <u>J. Biol Chem.</u> 274(21):14560-14567 (1999)	
	24	IRMLER et al., "Direct physical interaction between the Caenorhabditis elegans 'death proteins' CED-3 and CED-4," <u>FEBS Lett.</u> 406(1-2):189-190 (1997)	
	25	KOBÉ and DEISENHOFER, "Proteins with leucine-rich repeats," <u>Curr. Opin. Struct. Biol.</u> 5(3):409-416 (1995)	
	26	KOONIN and ARAVIND, "The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation," <u>TIBS</u> 25(5):223-224 (2000)	
	27	KRAJEWSKI et al., "Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia," <u>Proc. Natl. Acad. Sci. U S A.</u> 96(10):5752-5757 (1999)	
	28	LI et al., "Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade," <u>Cell</u> 91(4):479-489 (1997)	
	29	MARSHALL, E., "Gene therapy's growing pains," <u>Science</u> . 269(5227):1050-1055 (1995)	
	30	NAGASE et al., "Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins <i>in vitro</i> ," <u>DNA Res.</u> 5(5):277-86 (1998)	
	31	NAGASE et al., "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins <i>in vitro</i> ," <u>DNA Res.</u> 6(1):63-70 (1999)	
	32	OGURA et al., "Nod2, A Nod1/Apaf-1 Family Member That Is Restricted To Monocytes And Activates NF-kb," <u>J. Biol. Chem.</u> 276(7):4812-4818 (2001)	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTY. DOCKET NO. 066821-0281	SERIAL NO. 10/828,920
		APPLICANT Reed, John C.	
		FILING DATE April 20, 2004	GROUP 1633
	33	ORKIN and MOTULSKY, "Report and Recommendations of the Panel to Assess the NIH Investment In Research on Gene Therapy," National Institutes of Health, December 7, pgs. 1-39 (1995)	
	34	POYET et al., "Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1," <u>J. Biol. Chem.</u> 276(30):28309-28313 (2001)	
	35	QIN et al., "Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1," <u>Nature</u> 399(6736):549-557 (1999)	
	36	ROTHER et al., "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins," <u>Cell</u> 83(7):1243-1252 (1995)	
	37	RUSSELL and BARTON "Structural features can be unconserved in proteins with similar folds. An analysis of side-chain to side-chain contacts secondary structure and accessibility," <u>J Mol Biol.</u> 244(3):332-350 (1994)	
	38	RYCHLEWSKI et al., "Comparison of sequence profiles. Strategies for structural predictions using sequence information," <u>Protein Sci.</u> 9(2):232-241 (2000)	
	39	SALEH et al., "Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation," <u>J. Biol. Chem.</u> 274(25):17941-17945 (1999)	
	40	SATO et al., "Cloning and sequencing of a cDNA encoding the rat Bcl-2 protein," <u>Gene</u> 140(2):291-292 (1994)	
	41	SESHAGIRI and MILLER, " <i>Caenorhabditis elegans</i> CED-4 stimulates CED-3 processing and CED-3-induced apoptosis," <u>Curr Biol.</u> 7(7):455-460 (1997)	
	42	SHAHAM and HORVITZ, "An alternatively spliced <i>C. elegans ced-4</i> RNA encodes a novel cell death inhibitor," <u>Cell</u> 86(2):201-208 (1996)	
	43	SPECTOR et al., "Interaction between the <i>C. elegans</i> cell-death regulators CED-9 and CED-4," <u>Nature</u> 385:653-656 (1997)	
	44	SRINIVASULA et al., "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <u>Mol. Cell.</u> 1(7):949-57 (1998)	
	45	STAPLETON et al., "The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization," <u>Nat. Struct. Biol.</u> 6(1):44-49 (1999)	
	46	THOME et al., "Identification of CARDIAK, a RIP-like kinase that associates with caspase-1," <u>Curr. Biol.</u> 8(15):885-888 (1998)	
	47	THORNBERRY and LAZEBNIK, "Caspases: enemies within," <u>Science</u> 281(5381):1312-1316 (1998)	
	48	VAN DER BIEZEN and JONES, "The NB-ARC domain: a novel signalling motif shared by plant resistance gene products and regulators of cell death in animals," <u>Curr. Biol.</u> 8(7):R226-R227 (1998)	
	49	VERMA and SOMIA, "Gene therapy - promises, problems and prospects," <u>Nature</u> 389(6648):239-242 (1997)	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

[illegible]

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.